All products / Type / Easy Pen
Semaglutide 10mg - Easy Pen
GLP-1 receptor agonist — weight, blood-sugar & inflammation research
SKU: EP-SEM-10-1
99% Purity$155$124Save $31 (−20%)
- Format
- Easy Pen
- Dosage
- 0.05mg Per Click
- Capacity
- 10mg
Potential benefits
- Weight-management research
- Blood-sugar regulation research
- Visceral-fat research
- Liver-fat & hepatic research
- Cardiometabolic research
- Gut-brain signaling research
- Inflammation modulation
- Neuroprotective potential
Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) originally developed for type 2 diabetes, studied for a range of metabolic effects including body-weight reduction, appetite regulation, insulin sensitivity, and systemic inflammation. By mimicking the body’s natural GLP-1 hormone, semaglutide has been studied for its effects on blood glucose, satiety, and longer-term body composition.
Semaglutide is purported to work by mimicking the GLP-1 hormone, which is naturally released in response to food. It binds to GLP-1 receptors found in the pancreas, gut, brain, and other tissues, producing a cascade of potential beneficial metabolic effects. This peptide is studied for metabolic-research applications.
Semaglutide is purported to work by mimicking the GLP-1 hormone, which is naturally released in response to food. It binds to GLP-1 receptors found in the pancreas, gut, brain, and other tissues, producing a cascade of potential beneficial metabolic effects. This peptide is studied for metabolic-research applications.
- Studied for effects on appetite and caloric intake via satiety and gastric emptying; in the STEP 1 trial mean body-weight reduction was about 15% over 68 weeks, with a subset exceeding 20%
- Increases insulin secretion and decreases glucagon production in a glucose-dependent manner, and studied for effects on blood-glucose stability and HbA1c.
- Studied for effects on abdominal (visceral) fat and body composition relative to lifestyle intervention alone.
- Studied for effects on hepatic fat and liver histology in metabolic dysfunction-associated steatohepatitis (MASH) in the phase 3 ESSENCE trial.
- Studied for effects on blood pressure, lipids, and inflammatory markers; the SELECT trial examined cardiovascular outcomes in overweight or obese adults without diabetes.
- Studied for effects on central appetite regulation, including hunger and eating behavior.
- Studied for effects on systemic inflammation markers such as CRP, examined in a systematic review and meta-analysis of semaglutide trials.
- Preclinical and biomarker studies have explored effects on neuroinflammation; note the phase 3 EVOKE Alzheimer's trials did not show clinical efficacy.
References
- https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- https://www.nejm.org/doi/full/10.1056/NEJMoa2413258
- https://www.nature.com/articles/s41591-024-03018-2
- https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- https://www.sciencedaily.com/releases/2025/05/250527124029.htm
- https://peerj.com/articles/17891/
- https://www.mdpi.com/1422-0067/25/9/4972
| Molecular formula | C187H291N45O59 |
|---|---|
| Molecular weight | 4113.6 Da |
| CAS number | 910463-68-2 |
| Purity | 99% |
| Storage | Use within 30 days of first use. Store at 2–8°C / 35–46°F. Protect from sunlight. Do not freeze. |
Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(C18-diacid-gamma-Glu-OEG-OEG)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Synonyms: Semaglutide, Rybelsus, Ozempic, 910463-68-2, Wegovy
Research & background
Independent, research-focused reading. Educational references, not medical advice or product claims.
